The new results from the BREAKWATER study – which is testing the combination of BRAF inhibitor Braftovi (encorafenib) with Eli Lilly's Erbitux (cetuximab) and chemotherapy – showed a ...

No writing assistance was utilized in the production of this manuscript. BRAF, a member of a serine/threonine kinase protein family, serves as an immediate downstream effector of RAS in the MAPK ...

ARV-393 is Arvinas’ investigational PROteolysis TArgeting Chimera (PROTAC) degrader targeting the B-cell lymphoma 6 protein (BCL6), a transcriptional repressor and major driver of B-cell lymphomas.